It is with the heaviest of hearts that the Charcot-Marie-Tooth Association (CMTA) mourns the loss of our friend and Strategy to Accelerate Research (STAR) Scientific Advisory Board (SAB) Member, Dr. M. Laura Feltri. Dr. Feltri passed away December 25, 2023, ...
In a recent announcement, Vanda Pharmaceuticals Inc. shared that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its VCA-894A compound. This approval marks a significant step forward for community members who have ...
In a statement released on February 15, 2024, by Charcot-Marie-Tooth Association (CMTA) Alliance Partner, Applied Therapeutics, the company said that its INSPIRE Phase III trial for a certain type of Charcot-Marie-Tooth disease (CMT), called SORD-deficiency, showed positive interim 12-month results ...
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research that’s aimed at bringing treatments and a cure to patients of this rare disease, is pleased to announce the appointment of Dr. Charlotte Sumner to its Strategy ...
Multisite and multiyear collaborative project led by a team of international researchers
Advancing CMT Treatment with CRISPR-Cas9 and small molecule drug development
GLENOLDEN, PA, February 7, 2024 – The Charcot-Marie-Tooth Association (CMTA) announced today a groundbreaking international research initiative investing over ...